FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048842384> ?p ?o ?g. }

• W3048842384 endingPage "440" @default.
• W3048842384 startingPage "437" @default.
• W3048842384 abstract "ObjectivesAt the end of November 2019, a novel coronavirus responsible for respiratory tract infections (COVID-19) emerged in China. Despite drastic containment measures, this virus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), spread in Asia and Europe. The pandemic is ongoing with a particular hotspot in Southern Europe and America; many studies predicted a similar epidemic in Africa, as is currently seen in Europe and the United States of America. However, reported data have not confirmed these predictions. One of the hypotheses that could explain the later emergence and spread of COVID-19 pandemic in African countries is the use of antimalarial drugs to treat malaria, and specifically, artemisinin-based combination therapy (ACT).MethodsThe antiviral activity of fixed concentrations of ACT at concentrations consistent with those observed in human plasma when ACT is administered at oral doses for uncomplicated malaria treatment was evaluatedin vitro against a clinically isolated SARS-CoV-2 strain (IHUMI-3) in Vero E6 cells.ResultsMefloquine-artesunate exerted the highest antiviral activity with % inhibition of 72.1 ± 18.3 % at expected maximum blood concentration (Cmax) for each ACT drug at doses commonly administered in malaria treatment. All the other combinations, artesunate-amodiaquine, artemether-lumefantrine, artesunate-pyronaridine, or dihydroartemisinin-piperaquine, showed antiviral inhibition in the same ranges (27.1 to 34.1 %).ConclusionsAntimalarial drugs for which concentration data in the lungs are available are concentrated from 10 to 160 fold more in the lungs than in blood. Thesein vitro results reinforce the hypothesis that antimalarial drugs could be effective as an anti-COVID-19 treatment." @default.
• W3048842384 created "2020-08-18" @default.
• W3048842384 creator A5006021408 @default.
• W3048842384 creator A5006058996 @default.
• W3048842384 creator A5020915591 @default.
• W3048842384 creator A5023619971 @default.
• W3048842384 creator A5037478303 @default.
• W3048842384 creator A5038033557 @default.
• W3048842384 creator A5047690752 @default.
• W3048842384 creator A5065842132 @default.
• W3048842384 creator A5066198742 @default.
• W3048842384 creator A5070359853 @default.
• W3048842384 creator A5078098543 @default.
• W3048842384 creator A5080884543 @default.
• W3048842384 creator A5086028417 @default.
• W3048842384 date "2020-10-01" @default.
• W3048842384 modified "2023-10-18" @default.
• W3048842384 title "Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate" @default.
• W3048842384 cites W1525415484 @default.
• W3048842384 cites W2015883804 @default.
• W3048842384 cites W2068476392 @default.
• W3048842384 cites W2082954549 @default.
• W3048842384 cites W2104107121 @default.
• W3048842384 cites W2108284676 @default.
• W3048842384 cites W2120796946 @default.
• W3048842384 cites W2148721643 @default.
• W3048842384 cites W2169731328 @default.
• W3048842384 cites W2950234645 @default.
• W3048842384 cites W3001118548 @default.
• W3048842384 cites W3003217347 @default.
• W3048842384 cites W3006834170 @default.
• W3048842384 cites W3007683769 @default.
• W3048842384 cites W3007989190 @default.
• W3048842384 cites W3009456922 @default.
• W3048842384 cites W3009859788 @default.
• W3048842384 cites W3010930696 @default.
• W3048842384 cites W3016271937 @default.
• W3048842384 cites W3018057581 @default.
• W3048842384 cites W3025320502 @default.
• W3048842384 cites W3027173470 @default.
• W3048842384 doi "https://doi.org/10.1016/j.ijid.2020.08.032" @default.
• W3048842384 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7426697" @default.
• W3048842384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32805422" @default.
• W3048842384 hasPublicationYear "2020" @default.
• W3048842384 type Work @default.
• W3048842384 sameAs 3048842384 @default.
• W3048842384 citedByCount "77" @default.
• W3048842384 countsByYear W30488423842020 @default.
• W3048842384 countsByYear W30488423842021 @default.
• W3048842384 countsByYear W30488423842022 @default.
• W3048842384 countsByYear W30488423842023 @default.
• W3048842384 crossrefType "journal-article" @default.
• W3048842384 hasAuthorship W3048842384A5006021408 @default.
• W3048842384 hasAuthorship W3048842384A5006058996 @default.
• W3048842384 hasAuthorship W3048842384A5020915591 @default.
• W3048842384 hasAuthorship W3048842384A5023619971 @default.
• W3048842384 hasAuthorship W3048842384A5037478303 @default.
• W3048842384 hasAuthorship W3048842384A5038033557 @default.
• W3048842384 hasAuthorship W3048842384A5047690752 @default.
• W3048842384 hasAuthorship W3048842384A5065842132 @default.
• W3048842384 hasAuthorship W3048842384A5066198742 @default.
• W3048842384 hasAuthorship W3048842384A5070359853 @default.
• W3048842384 hasAuthorship W3048842384A5078098543 @default.
• W3048842384 hasAuthorship W3048842384A5080884543 @default.
• W3048842384 hasAuthorship W3048842384A5086028417 @default.
• W3048842384 hasBestOaLocation W30488423841 @default.
• W3048842384 hasConcept C159047783 @default.
• W3048842384 hasConcept C203014093 @default.
• W3048842384 hasConcept C2776120307 @default.
• W3048842384 hasConcept C2776992834 @default.
• W3048842384 hasConcept C2777199930 @default.
• W3048842384 hasConcept C2778048844 @default.
• W3048842384 hasConcept C2778059366 @default.
• W3048842384 hasConcept C2778118209 @default.
• W3048842384 hasConcept C2778371730 @default.
• W3048842384 hasConcept C2780780316 @default.
• W3048842384 hasConcept C2781160685 @default.
• W3048842384 hasConcept C71924100 @default.
• W3048842384 hasConcept C98274493 @default.
• W3048842384 hasConceptScore W3048842384C159047783 @default.
• W3048842384 hasConceptScore W3048842384C203014093 @default.
• W3048842384 hasConceptScore W3048842384C2776120307 @default.
• W3048842384 hasConceptScore W3048842384C2776992834 @default.
• W3048842384 hasConceptScore W3048842384C2777199930 @default.
• W3048842384 hasConceptScore W3048842384C2778048844 @default.
• W3048842384 hasConceptScore W3048842384C2778059366 @default.
• W3048842384 hasConceptScore W3048842384C2778118209 @default.
• W3048842384 hasConceptScore W3048842384C2778371730 @default.
• W3048842384 hasConceptScore W3048842384C2780780316 @default.
• W3048842384 hasConceptScore W3048842384C2781160685 @default.
• W3048842384 hasConceptScore W3048842384C71924100 @default.
• W3048842384 hasConceptScore W3048842384C98274493 @default.
• W3048842384 hasLocation W30488423841 @default.
• W3048842384 hasLocation W30488423842 @default.
• W3048842384 hasLocation W30488423843 @default.
• W3048842384 hasLocation W30488423844 @default.
• W3048842384 hasLocation W30488423845 @default.
• W3048842384 hasLocation W30488423846 @default.

• next